Neuroprotection in stroke by complement inhibition and immunoglobulin therapy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Activation of the complement system occurs in a variety of neuroinflammatory diseases and neurodegenerative processes of the CNS. Studies in the last decade have demonstrated that essentially all of the activation components and receptors of the complement system are produced by astrocytes, microglia, and neurons. There is also rapidly growing evidence to indicate an active role of the complement system in cerebral ischemic injury. In addition to direct cell damage, regional cerebral ischemia and reperfusion (I/R) induces an inflammatory response involving complement activation and generation of active fragments, such as C3a and C5a anaphylatoxins, C3b, C4b, and iC3b. The use of specific inhibitors to block complement activation or their mediators such as C5a, can reduce local tissue injury after I/R. Consistent with therapeutic approaches that have been successful in models of autoimmune disorders, many of the same complement inhibition strategies are proving effective in animal models of cerebral I/R injury. One new form of therapy, which is less specific in its targeting of complement than monodrug administration, is the use of immunoglobulins. Intravenous immunoglobulin (IVIG) has the potential to inhibit multiple components of inflammation, including complement fragments, pro-inflammatory cytokine production and leukocyte cell adhesion. Thus, IVIG may directly protect neurons, reduce activation of intrinsic inflammatory cells (microglia) and inhibit transendothelial infiltration of leukocytes into the brain parenchyma following an ischemic stroke. The striking neuroprotective actions of IVIG in animal models of ischemic stroke suggest a potential therapeutic potential that merits consideration for clinical trials in stroke patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 3×
“The donor pool size is typically around several thousand individuals, which provides a sufficiently large sample number to ensure homogenic consistency but functional heterogeneity (Nimmerjahn and Ravetch, 2008a).”
BackgroundRecapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849 · cited 2×
“The second involves IVIG binding to the various crystallizable fragment (Fc) receptors resulting in modulation of expression and function of Fc receptors, complement activation, and anti-inflammatory effects resulting from interference with proinflammatory cytokines, provision of anti-idiotypic antibodies and modulati…”
BackgroundProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 2×
“…activation could induce cell lysis and cause cell death (Shen et al., 1997; Fonseca et al., 2004); on the other side, complement components such as C1q and C3b can promote the clearance of cellular debris and apoptotic cells and enhance cell survival (Wyss-Coray et al., 2002; Rus et al., 2006).”
BackgroundYenari, M. A., Xu, L., Tang, X. N., Qiao, Y., & Giffard, R. G. (2006) · Stroke · doi:10.1161/01.str.0000206281.77178.ac · Cited by 359 · cited 1×
“Ischemic stroke enhances the interactions of vascular endothelial cells with extravascular brain cells (astrocytes, microglia, neurons) and intravascular cells (platelets and leukocytes), interactions that may contribute to the injury process (Yenari et al., 2006; Urra et al., 2008).”
BackgroundAbsence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345 · cited 2×
“On one side, complement activation could induce cell lysis and cause cell death (Shen et al., 1997; Fonseca et al., 2004); on the other side, complement components such as C1q and C3b can promote the clearance of cellular debris and apoptotic cells and enhance cell survival (Wyss-Coray et al.”
BackgroundStoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187
Activated microglial cells and complement factors are unrelated to cortical Lewy bodies
Rozemuller, A. J. M., Eikelenboom, P., Theeuwes, J. W., Jansen Steur, E. N. H., & de Vos, R. A. I. (2000) · Acta Neuropathologica · doi:10.1007/s004010000225 · Cited by 50 · cited 1×
“However, another study found no complement reactivity on Lewy bodies in the cingulate gyrus in PD (Rozemuller et al., 2000).”
Background
Cited by
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
“The complement cascade, a sequence of protein-protein interactions that ‘‘attacks’’ and damages cell membranes, may also be activated in the aging brain and is implicated in the pathogenesis of AD and ischemic stroke (Arumugam et al., 2009; Stephan et al., 2013; Hong et al., 2016).”
BackgroundSelf-citationInflammatory mechanisms in ischemic stroke: therapeutic approaches
Lakhan, S. E., Kirchgessner, A., & Hofer, M. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-97 · Cited by 1,072
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke
Woodruff, T. M., Thundyil, J., Tang, S.-C., Sobey, C. G., Taylor, S. M., & Arumugam, T. V. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-11 · Cited by 598
Self-citation
Metadata
- Authors
- Arumugam, T. V., Woodruff, T. M., Lathia, J. D., Selvaraj, P. K., Mattson, M. P., & Taylor, S. M.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 158
- Issue
- 3
- Pages
- 1074-1089
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2072205634
- Cited by
- 125
- References
- 8
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. https://app.cochat.ai/papers/10.1016/j.neuroscience.2008.07.015
- The paper
- Arumugam, T. V., Woodruff, T. M., Lathia, J. D., Selvaraj, P. K., Mattson, M. P., & Taylor, S. M. (2009). Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience. https://doi.org/10.1016/j.neuroscience.2008.07.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.